# Australia Medical Imaging Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2025-2032 --- ## Market Overview # CHAPTER 1 - Market Overview The Australia Medical Imaging Market operates through capital-equipment procurement, replacement cycles, software upgrades, maintenance contracts and hospital or outpatient imaging investment. Australia recorded around **30.0 million Medicare-subsidised diagnostic imaging services in 2024-25**, demonstrating a large recurring clinical workload. High scan volumes improve equipment utilisation and sustain demand for CT, MRI, ultrasound and digital radiography upgrades. Demand is concentrated in New South Wales, Victoria and Queensland, where population density, tertiary hospitals and private diagnostic networks support the deepest installed base. Nationally, Australia had **94 CT, MRI and PET scanners per million population in 2023 or nearest year**, versus an OECD average of 51. This equipment intensity makes replacement and productivity-led upgrades commercially important. Regulation combines TGA medical-device registration with Medicare reimbursement rules. From **1 July 2025**, MRI equipment-based Commonwealth licences were replaced by practice-based licences, making partial and previously ineligible MRI units at licensed practices fully Medicare-eligible. Proposed removal of MRI licensing from **1 July 2027** can broaden addressable utilisation and accelerate private-sector MRI investment. Australia remains structurally import-dependent for major imaging systems. Imports under HS 9022, covering X-ray and other ionising-radiation apparatus and related equipment, reached approximately **USD 449 million in 2024**; CT scanner imports alone were about **USD 113 million**. This supports global OEM participation but exposes procurement budgets to exchange rates, supply chains and overseas production cycles. ## KPIs at a Glance * Market Value: USD 1,030 million (2025) * Dominant Region: New South Wales * Dominant Segment: Computed Tomography Systems (fastest growing major modality) * Total Number of Players: 52 ## Future Outlook The Australia Medical Imaging Market is forecast to expand from USD 1,030 million in 2025 to USD 1,569 million by 2032, representing a 6.20% forecast CAGR. This compares with an estimated 5.72% historical CAGR during 2020-2025. The growth profile reflects equipment replacement, increasing scan intensity, broader MRI reimbursement eligibility and demand for higher-throughput platforms. CT, MRI and ultrasound procurement should increasingly incorporate AI reconstruction, automated positioning and workflow software. Value growth is expected to remain moderately above physical system-volume growth because premium platforms, software subscriptions, detector upgrades and multi-year service agreements increase revenue per installed system. By 2032, procurement economics are expected to shift toward lifecycle productivity rather than equipment acquisition price alone. Photon-counting and spectral CT, low-helium MRI, portable imaging and AI-assisted workflow tools can improve throughput while reducing repeat scans and technician workload. Australia already operates an imaging-equipment density materially above the OECD average, making replacement demand more important than first-time modality penetration in metropolitan markets. Regional locations retain capacity whitespace, supported by reimbursement reform and public investment. The principal constraint will be skilled workforce availability, particularly radiographers and sonographers, which increases the strategic value of automation, remote support, managed-equipment arrangements and productivity-enhancing software. --- | | | | --- | --- | | **6.20%** Forecast CAGR (2025-2032) | **$1,569 Mn** 2032 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2025-2032** | Historical CAGR **5.72%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** Australia * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2025-2032 (base year inclusive) * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn/Bn ### Segmentation Data Tree * Product Type + Ionising Imaging Systems - Digital Radiography Systems - Computed Tomography Systems - Nuclear Medicine Systems + Magnetic Resonance Systems - 1.5T MRI Systems - 3T and Higher MRI Systems + Ultrasound Systems - Cart-Based Ultrasound - Compact and Handheld Ultrasound + Hybrid Imaging Systems - PET/CT Systems - SPECT/CT Systems * Care Setting + Public Hospitals - Tertiary Hospitals - Regional Hospitals + Private Hospitals - General Private Hospitals - Specialist Private Hospitals + Diagnostic Imaging Centres - Multi-Site Radiology Networks - Independent Imaging Centres + Ambulatory and Point-of-Care Sites - Specialist Clinics - Emergency and Mobile Settings * End User + Radiology Departments - General Diagnostic Radiology - Interventional Radiology + Cardiology Departments - Cardiac CT and MRI - Echocardiography + Oncology Departments - Cancer Diagnosis - Therapy Planning + Women's Health Providers - Breast Imaging - Obstetric and Gynaecological Imaging * Disease Area + Oncology - Solid Tumour Imaging - Cancer Screening + Cardiovascular - Coronary Imaging - Structural Heart Imaging + Musculoskeletal - Orthopaedic Imaging - Sports Medicine Imaging + Neurology - Stroke Imaging - Neurodegenerative Disease Imaging * Channel + Direct OEM Sales - Hospital Account Sales - Private Network Sales + Group Purchasing and Tenders - Public Procurement - Hospital Group Procurement + Authorized Distributors - National Distributors - Specialist Modality Distributors + Managed Equipment Services - Multi-Year Equipment Contracts - Lifecycle Service Agreements * Technology + Conventional Digital Imaging - Digital Detector Platforms - Standard Reconstruction + AI-Enabled Reconstruction - Deep-Learning Reconstruction - Automated Workflow + Photon-Counting and Spectral Imaging - Photon-Counting CT - Dual-Energy CT + Portable and Point-of-Care Imaging - Handheld Ultrasound - Mobile Digital X-Ray * Geography + New South Wales - Sydney Metropolitan - Regional New South Wales + Victoria - Melbourne Metropolitan - Regional Victoria + Queensland - South East Queensland - Regional Queensland + Rest of Australia - Western and South Australia - Tasmania and Territories --- ## Market Trajectory # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. | Year | Market Size (USD Mn) | | --- | --- | | 2020 | 780 | | 2021 | 815 | | 2022 | 860 | | 2023 | 914 | | 2024 | 969 | | 2025 | 1,030 | | 2026F | 1,095 | | 2027F | 1,165 | | 2028F | 1,238 | | 2029F | 1,315 | | 2030F | 1,397 | | 2031F | 1,482 | | 2032F | 1,569 | | Year | YoY Growth Rate (%) | | --- | --- | | 2021 | 4.49% | | 2022 | 5.52% | | 2023 | 6.28% | | 2024 | 6.02% | | 2025 | 6.30% | | 2026F | 6.31% | | 2027F | 6.39% | | 2028F | 6.27% | | 2029F | 6.22% | | 2030F | 6.24% | | 2031F | 6.08% | | 2032F | 5.87% | | Year | Market Value Growth (%) | System-Equivalent Volume Growth (%) | | --- | --- | --- | | 2020 | 0.00% | 0.00% | | 2021 | 4.49% | 3.20% | | 2022 | 5.52% | 4.10% | | 2023 | 6.28% | 4.80% | | 2024 | 6.02% | 4.60% | | 2025 | 6.30% | 4.90% | | 2026 | 6.31% | 5.00% | | 2027 | 6.39% | 5.20% | | 2028 | 6.27% | 5.10% | | 2029 | 6.22% | 5.00% | | 2030 | 6.24% | 5.00% | | 2031 | 6.08% | 4.90% | | 2032 | 5.87% | 4.70% | ### Historical Market Performance (2020-2025) Market expansion accelerated after the pandemic-era disruption as deferred equipment replacement, higher examination volumes and hospital capital programs returned. The strongest annual increase occurred in 2025 at 6.30%, following 6.28% in 2023. Australia also experienced more than a 50% increase in CT examination rates between 2013 and 2023, according to OECD analysis, reinforcing the structural utilisation case for higher-throughput systems. Increased private diagnostic-network investment and digital detector replacement supported radiography and ultrasound demand alongside advanced modalities. ### Forecast Market Outlook (2025-2032) The market is projected to deliver a 6.20% CAGR through 2032. Growth is expected to be led by premium CT, MRI, portable ultrasound and software-enabled equipment rather than basic system additions alone. Lifecycle revenue should increase as hospitals procure AI reconstruction, cybersecurity upgrades and longer service agreements alongside hardware. Reimbursement liberalisation for MRI lowers utilisation barriers, while the transition toward photon-counting CT and automated scanning lifts average equipment value. Volume growth remains below value growth as product mix shifts toward higher-specification platforms and digitally enabled upgrade packages. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Australia Medical Imaging Market is moving from a predominantly hardware-replacement cycle toward a combination of modality upgrades, AI-supported workflow and service-intensive procurement. The KPI series below combines market values with internally reconciled operating indices used to evaluate replacement intensity, technology mix and equipment demand. | Year | Market Size (USD Mn) | YoY Growth (%) | Major Imaging System Shipment Index (2025=100) | Replacement Demand Share (%) | AI-Enabled New System Share (%) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 780 | - | 78 | 52% | 18% | Historical | | 2021 | 815 | 4.49% | 82 | 53% | 22% | Historical | | 2022 | 860 | 5.52% | 87 | 54% | 28% | Historical | | 2023 | 914 | 6.28% | 92 | 55% | 35% | Historical | | 2024 | 969 | 6.02% | 96 | 56% | 42% | Historical | | 2025 | 1,030 | 6.30% | 100 | 57% | 50% | Base Year | | 2026 | 1,095 | 6.31% | 105 | 58% | 58% | Forecast and Latest Operating KPIs | | 2027 | 1,165 | 6.39% | 110 | 59% | 65% | Forecast and Industry Outlook | | 2028 | 1,238 | 6.27% | 116 | 60% | 72% | Forecast and Industry Outlook | | 2029 | 1,315 | 6.22% | 122 | 61% | 78% | Forecast and Industry Outlook | | 2030 | 1,397 | 6.24% | 128 | 62% | 83% | Forecast and Industry Outlook | | 2031 | 1,482 | 6.08% | 134 | 63% | 87% | Forecast and Industry Outlook | | 2032 | 1,569 | 5.87% | 140 | 64% | 90% | Forecast and Industry Outlook | **KPI 1, Major Imaging System Shipment Index:** **100 (2025, Australia)**. Replacement and capacity additions are supported by sustained scan volumes. More than 27 million Medicare-subsidised diagnostic imaging services were delivered in 2022-23, demonstrating a large installed-base workload. **KPI 2, Replacement Demand Share:** **57% (2025, Australia model)**. Australia's high equipment density makes replacement economics central to procurement. The country records 94 CT, MRI and PET scanners per million population compared with an OECD average of 51. **KPI 3, AI-Enabled New System Share:** **50% (2025, Australia model)**. AI increasingly enters reconstruction, triage and workflow layers. The TGA maintains a dedicated list of AI-enabled medical devices in the ARTG, updated through July 2026. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Product Type | **Fastest Growing Segment:** Technology | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Ionising Imaging Systems; Magnetic Resonance Systems; Ultrasound Systems; Hybrid Imaging Systems | | 2 | Care Setting | Public Hospitals; Private Hospitals; Diagnostic Imaging Centres; Ambulatory and Point-of-Care Sites | | 3 | End User | Radiology Departments; Cardiology Departments; Oncology Departments; Women's Health Providers | | 4 | Disease Area | Oncology; Cardiovascular; Musculoskeletal; Neurology | | 5 | Channel | Direct OEM Sales; Group Purchasing and Tenders; Authorized Distributors; Managed Equipment Services | | 6 | Technology | Conventional Digital Imaging; AI-Enabled Reconstruction; Photon-Counting and Spectral Imaging; Portable and Point-of-Care Imaging | | 7 | Geography | New South Wales; Victoria; Queensland; Rest of Australia | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns. **Product Type** - Product mix remains the strongest revenue-allocation axis because CT, MRI, ultrasound, radiography and molecular-imaging platforms have materially different capital costs, replacement cycles and service economics. Ionising imaging systems represent the broadest installed equipment pool, while CT contributes an important premium revenue component as providers prioritize faster acquisition, dose reduction and spectral capability. **Technology** - Technology is the fastest-changing strategic dimension as hospitals and imaging networks increasingly evaluate AI reconstruction, photon-counting CT, automation and portable imaging. AI-enabled reconstruction is expected to be the most rapidly adopted Level-2 category because it can increase scanner throughput, improve image quality and extend the productive life of installed hardware without requiring every site to undertake full platform replacement. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis Australia occupies a high-value position among advanced Asia-Pacific and comparable OECD medical-imaging markets, supported by high equipment density, universal health-system reimbursement and mature hospital infrastructure. Its installed CT, MRI and PET equipment intensity is substantially above the OECD average. ### KPI Summary * Focus Country Ranking: **2nd** * Focus Country Market Size: **USD 1,030 Mn** * Australia CAGR (2025-2032): **6.20%** | Country | Market Size | CAGR (%) | Health Spending per Capita (USD PPP) | CT, MRI and PET Units per Mn Population | | --- | --- | --- | --- | --- | | Australia | USD 1,030 Mn | 6.20% | 7,469 | 94 | | Japan | USD 2,850 Mn | 5.91% | 5,000+ | 100+ | | Canada | USD 932 Mn | 2.60% | 7,000+ | 26 | | South Korea | USD 694 Mn | 5.90% | 4,500+ | 87 | | New Zealand | USD 190 Mn | 6.00% | 5,500+ | 65 | ### Market Position Australia ranks second within the selected peer set, behind Japan, with a 2025 equipment market of USD 1,030 Mn and one of the OECD's highest advanced-imaging equipment densities. ### Growth Advantage Australia's 6.20% modeled CAGR exceeds Canada's reported 2.60% and is broadly comparable with Japan's approximately 5.91%, reflecting stronger MRI reimbursement reform and replacement-cycle momentum. ### Competitive Strengths Australia combines USD PPP 7,469 health spending per capita with 94 CT, MRI and PET systems per million people, supporting premium replacement demand and technology-led procurement. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Australia Medical Imaging Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### Rising Diagnostic Imaging Utilisation Clinical throughput remains structurally high, with approximately **30.0 million services (2024-25, Australia)** supporting recurring equipment utilisation and replacement. * More than **27 million services (2022-23, Australia)** were Medicare-subsidised diagnostic imaging procedures, demonstrating substantial recurring utilisation across radiography, ultrasound, CT, MRI and nuclear medicine. * Approximately **39% of Australians (2022-23, Australia)** received at least one Medicare-subsidised diagnostic imaging service, widening the revenue base for imaging networks and equipment vendors. * Australian CT examination rates increased by **more than 50% (2013-2023, Australia)**, reinforcing demand for higher-throughput CT platforms and replacement of ageing scanners. ### Ageing Population and Disease Burden Australia's diagnostic workload is reinforced by approximately **170,000 new cancer cases (2025, Australia)**, supporting oncology and cross-sectional imaging demand. * Cancer diagnoses increased from around 88,000 in 2000 to approximately **170,000 cases (2025, Australia)**, creating sustained demand for CT, MRI, PET and image-guided treatment planning. * Australian hospitals recorded approximately **12.8 million hospitalisations (2024-25, Australia)**, maintaining high imaging demand across emergency, surgical, oncology and inpatient pathways. * The health system included **704 public hospitals (2023-24, Australia)**, creating a broad institutional procurement base for fixed and mobile diagnostic imaging equipment. ### MRI Reimbursement and Medicare Reform Practice-based MRI licensing introduced on **1 July 2025 (Australia)** expands reimbursable utilisation and improves equipment investment economics. * Partial and previously ineligible MRIs at practices holding existing licences became fully eligible from **1 July 2025 (Australia)**, raising potential scanner utilisation. * Subject to legislation, MRI equipment licensing is scheduled for removal from **1 July 2027 (Australia)**, potentially reducing a structural barrier to new installations. * Diagnostic imaging MBS indexation for ultrasound, CT, radiology and MRI increased by **2.4% from July 2025 (Australia)**, supporting provider economics amid equipment and labour cost inflation. --- ## Market Challenges ### Medical Imaging Workforce Constraints Medical diagnostic radiographers remained classified in **national shortage status (2025, Australia)**, constraining utilisation even where scanner capacity is available. * Medical diagnostic radiography is identified as a **shortage occupation (2025, Australia)**, increasing recruitment costs and making automated positioning and reconstruction economically valuable. * High scanner density of **94 advanced systems per million people (2023 or nearest year, Australia)** means workforce availability can become a binding productivity constraint rather than hardware availability alone. * Workforce scarcity shifts procurement toward automation, remote applications support and systems capable of standardized protocols, increasing vendor differentiation around workflow rather than image quality alone. **30.0 million imaging services (2024-25, Australia)** intensify this requirement. ### High Import Dependence and Capital Exposure Australia imported approximately **USD 449 million of HS 9022 equipment (2024, Australia)**, exposing capital budgets to global supply chains and exchange rates. * CT scanner imports alone totaled approximately **USD 113 million (2024, Australia)**, showing material reliance on overseas high-value equipment manufacturing. * The United States supplied approximately **USD 129 million (2024, Australia)** of HS 9022 equipment, while Germany supplied about USD 94 million, concentrating procurement exposure among major manufacturing origins. * Imported capital intensity increases the importance of multi-year service agreements and lifecycle financing because hospitals must manage equipment refreshes alongside software, detector and magnet-related costs. **USD 449 million of HS 9022 imports (2024, Australia)** illustrates the scale of exposure. ### Regulatory and Digital Compliance Complexity Medical imaging vendors face expanding compliance obligations as UDI requirements begin for higher-risk devices from **1 July 2026 (Australia)**. * Australia's medical-device framework requires registration, classification and conformity assessment under the **Medical Devices Regulations 2002**, affecting time-to-market and evidence requirements. * Mandatory UDI compliance starts with Class III and IIb devices on **1 July 2026 (Australia)**, increasing data-governance and traceability requirements for manufacturers and sponsors. * The TGA's AI-enabled device register was updated through **27 July 2026 (Australia)**, reinforcing the need for imaging-software suppliers to integrate clinical, regulatory and post-market evidence processes. --- ## Market Opportunities ### AI-Enabled Workflow and Reconstruction Australia's **30.0 million annual imaging-service workload (2024-25)** creates a monetizable productivity case for AI-enabled reconstruction, triage and workflow tools. * Vendors can monetize AI through equipment bundles, upgrade licences and recurring software agreements, particularly where scanner throughput is constrained by workforce shortages. **Medical diagnostic radiographers were shortage-listed in 2025**. * Hospitals and diagnostic networks benefit where reconstruction reduces scan times or repeat examinations, improving asset productivity across an installed base of **94 advanced scanners per million population**. * Commercial scaling requires ARTG compliance and transparent clinical validation as the TGA continues updating its AI-enabled device list, including entries reported after **March 2025**. ### Regional MRI and Advanced Imaging Expansion Planned MRI deregulation from **1 July 2027 (Australia)** creates investment opportunities in regional and underserved catchments where reimbursement historically constrained capacity. * Investors and radiology operators can target underserved catchments using smaller-footprint MRI and managed-equipment models as licensing constraints reduce after **2027**. * Regional healthcare received a federal package of approximately **USD-equivalent public funding supported by AUD 213.6 million (2024-25 policy package, Australia)** for medicines, scans and related access initiatives. * Opportunity realization requires radiographer recruitment, remote specialist reporting and equipment-service coverage, making integrated hardware, software and support contracts more attractive than standalone scanner sales. ### Premium Replacement and Photon-Counting CT Australia's high installed-base intensity of **94 CT, MRI and PET systems per million people** creates a sizeable premium replacement opportunity. * OEMs can capture higher revenue per replacement through photon-counting, spectral imaging and advanced reconstruction rather than competing solely on equipment price. CT imports reached **USD 113 million (2024, Australia)**. * Hospitals benefit from upgrades that improve diagnostic confidence and throughput while reducing repeat imaging, important in a system handling approximately **12.8 million hospitalisations (2024-25, Australia)**. * Procurement models must shift from upfront capital comparisons to total lifecycle economics covering uptime, energy, software, detector replacement and workflow productivity, particularly as advanced technologies command premium acquisition prices. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview Competition is concentrated among global imaging OEMs with established Australian service networks, although modality specialists remain important in ultrasound, mammography, digital radiography and emerging premium imaging systems. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | GE HealthCare | - | Chicago, United States | 2023 | CT, MRI, ultrasound, molecular imaging, X-ray and imaging software | | Siemens Healthineers | - | Erlangen, Germany | 2017 | CT, MRI, molecular imaging, X-ray and advanced imaging software | | Philips | - | Amsterdam, Netherlands | 1891 | MRI, CT, radiography, ultrasound and enterprise imaging | | Canon Medical Systems | - | Otawara, Japan | - | CT, MRI, ultrasound, angiography and healthcare IT | | Fujifilm | - | Tokyo, Japan | 1934 | Digital radiography, CT, MRI, ultrasound and PACS | | Hologic | - | Marlborough, United States | 1985 | Mammography, breast imaging and image-analysis software | | Mindray | - | Shenzhen, China | 1991 | Diagnostic and point-of-care ultrasound systems | | Carestream Health | - | Rochester, United States | 2007 | Digital radiography, mobile X-ray and imaging workflow | | Esaote | - | Genoa, Italy | 1982 | Ultrasound, dedicated MRI and imaging IT | | United Imaging Healthcare | - | Shanghai, China | 2011 | CT, MRI, molecular imaging and digital imaging platforms | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * Installed Imaging System Base * Service Network Coverage * Australia Imaging Revenue Growth * Lifecycle Service Revenue Mix ### Analysis Covered * **Market Share Analysis:** Evaluates modality-specific competitive positions across Australian imaging equipment categories. * **Cross Comparison Matrix:** Benchmarks installed base, service coverage, revenue growth and mix. * **SWOT Analysis:** Assesses technology strengths, channel gaps, regulatory risks and opportunities. * **Pricing Strategy Analysis:** Compares capital pricing, lifecycle contracts, upgrades and managed services. * **Company Profiles:** Reviews portfolios, positioning, Australian presence and technology differentiation strategies. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, replacement cycle, recurring service revenue, consolidation, ROI * **Corporates:** modality demand, tender pipeline, pricing, installed base, upgrades * **Government:** imaging access, reimbursement, workforce, regulation, regional capacity * **Operators:** scanner utilization, throughput, staffing, uptime, lifecycle economics * **Financial institutions:** equipment finance, cash flow, utilization, residual values, covenants ### What You'll Gain * Market sizing and trajectory * Policy and compliance mapping * Equipment demand indicators * Segment structure and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Medicare diagnostic imaging utilisation analysis * TGA imaging device registration review * Medical equipment trade flow assessment * Hospital imaging capacity benchmark analysis #### Primary Research * Radiology department directors interviewed * Medical imaging procurement managers interviewed * OEM imaging sales leaders interviewed * Diagnostic network operations managers interviewed #### Validation and Triangulation * 286 respondents across imaging ecosystem * OEM and provider estimates reconciled * Trade and utilisation anchors compared * Forecast assumptions independently stress-tested ### Phase 2: Market Size Estimation #### Top-Down Assessment * National diagnostic imaging equipment expenditure and import pool * Breakdown across hospitals, imaging centres and specialist clinics * Medicare utilisation and public hospital infrastructure benchmarks #### Bottom-Up Modeling * Vendor-level equipment shipment and installed-base benchmarks * Modality-specific equipment pricing and service contract assumptions * System volumes multiplied by blended lifecycle revenue #### Forecasting and Scenario Analysis * Scan volume, ageing, replacement and reimbursement variables * MRI deregulation, workforce and technology adoption scenarios * Baseline, optimistic, and constrained projections through 2032 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the Australia Medical Imaging Market value chain from equipment supply and distribution through clinical procurement, operation and specialist imaging delivery. * Imaging Equipment OEMs * Hospital Imaging Departments * Diagnostic Imaging Networks * Technology and Service Partners #### Sample Size Respondents were engaged across equipment, procurement and clinical-operating segments to establish representative coverage of the Australia Medical Imaging Market. * Imaging Equipment OEMs - 68 respondents (Country Sales Directors, Product Managers) * Hospital Imaging Departments - 82 respondents (Radiology Directors, Chief Radiographers) * Diagnostic Imaging Networks - 74 respondents (Operations Directors, Clinical Directors) * Technology and Service Partners - 62 respondents (Service Managers, Applications Specialists) #### Validation and Triangulation Findings were validated across supplier, buyer and clinical-operating respondent cohorts to reduce single-source bias within the Australia Medical Imaging Market. * OEM shipment estimates cross-checked with procurement * Equipment volumes reconciled with installed-base indicators * Clinical demand compared with operating utilisation * Market forecasts tested against replacement economics --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What is the size of the Australia Medical Imaging Market in 2025? **A:** The Australia Medical Imaging Market was valued at USD 1,030 million in 2025. The estimate covers diagnostic imaging equipment, integrated equipment software and OEM lifecycle revenue associated with CT, MRI, radiography, ultrasound and molecular or hybrid imaging systems, while excluding revenues earned by radiology service providers for performing scans. The scale is supported by high equipment intensity and approximately 30.0 million Medicare-subsidised diagnostic imaging services during 2024-25. Australia's reliance on imported advanced systems also creates a substantial identifiable equipment trade pool. **Data used:** USD 1,030 million market value (2025); 30.0 million Medicare-subsidised imaging services (2024-25) **So what:** Australia is a meaningful developed-market revenue pool where replacement, software and service economics matter more than basic equipment penetration. #### Q: How fast will the Australia Medical Imaging Market grow through 2032? **A:** The market is forecast to reach USD 1,569 million by 2032, representing a 6.20% CAGR from the 2025 base. Growth is expected to be driven by CT and MRI replacement, MRI reimbursement liberalisation, portable ultrasound, AI-enabled reconstruction and premium imaging upgrades. The forecast assumes value growth remains slightly ahead of physical equipment-volume growth as software, service agreements and advanced system configurations increase revenue per deployment. Growth progressively moderates toward the end of the period as metropolitan installed-base penetration remains high. **Data used:** USD 1,569 million forecast value (2032); 6.20% CAGR (2025-2032) **So what:** Investment attractiveness is strongest in technology-led replacement, recurring software and lifecycle service revenue rather than commodity hardware alone. #### Q: Where will the largest profit-pool shift occur? **A:** The largest profit-pool shift is expected from one-time hardware transactions toward premium systems, software upgrades and recurring lifecycle services. Australia's high installed advanced-imaging density increases the number of systems entering replacement and upgrade cycles. AI reconstruction can extend scanner productivity, while managed-equipment services move customer spending into longer contractual relationships. Premium CT, MRI and enterprise imaging platforms also create aftermarket demand for applications, cybersecurity, maintenance and advanced visualization, allowing vendors to capture revenue throughout the system lifecycle rather than only at initial procurement. **Data used:** 94 CT, MRI and PET systems per million population (2023 or nearest year); 57% replacement-demand share model (2025) **So what:** Vendors should optimize lifecycle contract penetration and installed-base monetization rather than compete primarily on acquisition price. #### Q: What is the biggest constraint on medical imaging growth in Australia? **A:** Workforce availability is one of the most important operating constraints. Medical diagnostic radiography remained classified as an occupation in shortage in the 2025 national shortage framework. High scanner density does not automatically translate into additional procedure capacity if radiographers, sonographers and radiologists are unavailable. This increases the commercial value of automated patient positioning, protocol standardisation, AI reconstruction, remote applications support and productivity-enhancing workflow systems. Workforce limitations may also slow new regional installations where staffing economics are less attractive than metropolitan locations. **Data used:** Medical Diagnostic Radiographer shortage classification (2025); 94 advanced scanners per million population **So what:** Technology providers that demonstrably increase throughput per staff hour can gain a stronger procurement advantage. #### Q: How does Australia compare with other developed imaging markets? **A:** Australia is unusually equipment-intensive for its population size. OECD data indicate around 94 CT, MRI and PET systems per million population, versus an OECD average of roughly 51. This positions Australia above New Zealand and Canada on advanced equipment density and supports a mature replacement market. Japan remains larger and has exceptionally high CT and MRI availability, but Australia's combination of universal reimbursement, high healthcare spending and active private diagnostic networks creates attractive economics for premium systems and ongoing service revenue. **Data used:** Australia 94 advanced imaging systems per million population; OECD average 51 **So what:** Market-entry strategies should emphasize premium replacement and productivity improvements rather than relying on first-time equipment penetration. #### Q: What demand factor has the greatest long-term impact on imaging equipment? **A:** Rising diagnostic intensity across chronic disease, cancer and hospital care is the most durable underlying demand factor. Australia is expected to record around 170,000 new cancer diagnoses in 2025, while hospitals handled approximately 12.8 million admissions in 2024-25. These patient volumes drive repeated use of CT, MRI, ultrasound, radiography and molecular imaging for diagnosis, staging, treatment planning and follow-up. Unlike a one-off procurement incentive, disease-driven imaging intensity supports utilization throughout equipment replacement cycles and therefore strengthens long-term service and upgrade revenue. **Data used:** 170,000 estimated cancer diagnoses (2025); 12.8 million hospitalisations (2024-25) **So what:** Oncology, emergency imaging and high-throughput hospital applications remain priority areas for portfolio allocation. #### Q: How will MRI reimbursement reform influence investment decisions? **A:** MRI reimbursement reform improves the economics of both existing and future installations. From July 2025, equipment-based Commonwealth licences were replaced by practice-based licences, and partial or ineligible scanners at licensed practices became fully Medicare-eligible. Subject to legislation, the equipment-licensing requirement is planned for removal from July 2027. This lowers a historical barrier between scanner installation and reimbursement eligibility, particularly for private operators and regional providers evaluating additional capacity. Workforce, referral density and capital returns will nevertheless remain critical site-selection variables. **Data used:** Practice-based licensing from 1 July 2025; proposed equipment-licensing removal from 1 July 2027 **So what:** Imaging networks should reassess regional MRI catchments and investment thresholds ahead of the proposed 2027 transition. --- ## Table of Contents # Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases, Market Assessment, Go-To-Market Strategy, and Survey, delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Australia Medical Imaging Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Australia Medical Imaging Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Australia Medical Imaging Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Rising Diagnostic Imaging Utilisation ##### 3.1.2 Ageing Population and Disease Burden ##### 3.1.3 MRI Reimbursement and Medicare Reform #### 3.2 Market Challenges ##### 3.2.1 Medical Imaging Workforce Constraints ##### 3.2.2 High Import Dependence and Capital Exposure ##### 3.2.3 Regulatory and Digital Compliance Complexity #### 3.3 Market Opportunities ##### 3.3.1 AI-Enabled Workflow and Reconstruction ##### 3.3.2 Regional MRI and Advanced Imaging Expansion ##### 3.3.3 Premium Replacement and Photon-Counting CT #### 3.4 Market Trends ##### 3.4.1 AI-Accelerated Image Reconstruction ##### 3.4.2 Photon-Counting CT Adoption ##### 3.4.3 Portable Point-of-Care Imaging ##### 3.4.4 Lifecycle Service Contract Expansion #### 3.5 Government Regulation ##### 3.5.1 TGA Medical Device Registration ##### 3.5.2 MRI Practice-Based Licensing ##### 3.5.3 Unique Device Identification Requirements ##### 3.5.4 AI-Enabled Medical Device Regulation ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Australia Medical Imaging Market Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Australia Medical Imaging Market Segmentation #### 8.1 Product Type ##### 8.1.1 Ionising Imaging Systems ##### 8.1.2 Magnetic Resonance Systems ##### 8.1.3 Ultrasound Systems ##### 8.1.4 Hybrid Imaging Systems #### 8.2 Care Setting ##### 8.2.1 Public Hospitals ##### 8.2.2 Private Hospitals ##### 8.2.3 Diagnostic Imaging Centres ##### 8.2.4 Ambulatory and Point-of-Care Sites #### 8.3 End User ##### 8.3.1 Radiology Departments ##### 8.3.2 Cardiology Departments ##### 8.3.3 Oncology Departments ##### 8.3.4 Women's Health Providers #### 8.4 Disease Area ##### 8.4.1 Oncology ##### 8.4.2 Cardiovascular ##### 8.4.3 Musculoskeletal ##### 8.4.4 Neurology #### 8.5 Channel ##### 8.5.1 Direct OEM Sales ##### 8.5.2 Group Purchasing and Tenders ##### 8.5.3 Authorized Distributors ##### 8.5.4 Managed Equipment Services #### 8.6 Technology ##### 8.6.1 Conventional Digital Imaging ##### 8.6.2 AI-Enabled Reconstruction ##### 8.6.3 Photon-Counting and Spectral Imaging ##### 8.6.4 Portable and Point-of-Care Imaging #### 8.7 Geography ##### 8.7.1 New South Wales ##### 8.7.2 Victoria ##### 8.7.3 Queensland ##### 8.7.4 Rest of Australia ### 9. Australia Medical Imaging Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 Installed Imaging System Base ##### 9.2.4 Service Network Coverage ##### 9.2.5 Australia Imaging Revenue Growth ##### 9.2.6 Lifecycle Service Revenue Mix #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 GE HealthCare ##### 9.5.2 Siemens Healthineers ##### 9.5.3 Philips ##### 9.5.4 Canon Medical Systems ##### 9.5.5 Fujifilm ##### 9.5.6 Hologic ##### 9.5.7 Mindray ##### 9.5.8 Carestream Health ##### 9.5.9 Esaote ##### 9.5.10 United Imaging Healthcare ### 10. Australia Medical Imaging Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 Public Hospital Tender Procurement ##### 10.1.2 Private Hospital Capital Procurement ##### 10.1.3 Diagnostic Network Standardization ##### 10.1.4 Specialist Clinic Equipment Selection #### 10.2 Corporate Spend Patterns ##### 10.2.1 CT Replacement Capital Allocation ##### 10.2.2 MRI Lifecycle Spending ##### 10.2.3 Ultrasound Fleet Refresh ##### 10.2.4 Software and Service Contract Spend #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Imaging Workforce Constraints ##### 10.3.2 Scanner Utilization Bottlenecks ##### 10.3.3 Capital Budget Limitations ##### 10.3.4 Technology Integration Complexity #### 10.4 User Readiness for Adoption ##### 10.4.1 AI Reconstruction Readiness ##### 10.4.2 Photon-Counting CT Readiness ##### 10.4.3 Portable Imaging Readiness ##### 10.4.4 Cloud Imaging Readiness #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Examination Throughput Improvement ##### 10.5.2 Repeat Scan Reduction ##### 10.5.3 Workforce Productivity Improvement ##### 10.5.4 Multi-Site Workflow Expansion ### 11. Australia Medical Imaging Market Future Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Regional MRI Capacity Whitespace #### 1.2 AI Upgrade Revenue Whitespace #### 1.3 Managed Equipment Service Models #### 1.4 Portable Imaging Expansion ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Productivity Positioning #### 2.2 Total Cost of Ownership Messaging #### 2.3 Workforce Efficiency Positioning #### 2.4 Regional Access Positioning ### 3. Distribution Plan #### 3.1 Direct Hospital Account Coverage #### 3.2 Diagnostic Network Account Strategy #### 3.3 Specialist Distributor Coverage #### 3.4 Regional Service Network Design ### 4. Channel and Pricing Gaps #### 4.1 Capital Purchase Gaps #### 4.2 Managed Equipment Pricing #### 4.3 AI Subscription Pricing #### 4.4 Regional Service Pricing ### 5. Unmet Demand and Latent Needs #### 5.1 Regional MRI Access #### 5.2 Radiographer Productivity Tools #### 5.3 Faster CT Workflow #### 5.4 Portable Imaging Capacity ### 6. Customer Relationship #### 6.1 Strategic Hospital Accounts #### 6.2 Radiology Network Partnerships #### 6.3 Clinical Applications Support #### 6.4 Lifecycle Service Management ### 7. Value Proposition #### 7.1 Higher Scanner Throughput #### 7.2 Reduced Lifecycle Cost #### 7.3 Improved Diagnostic Capability #### 7.4 Simplified Clinical Workflow ### 8. Key Activities #### 8.1 ARTG Regulatory Registration #### 8.2 Clinical Reference Site Development #### 8.3 Service Engineer Network Expansion #### 8.4 Tender Pipeline Development ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Establish Australian Sponsor Structure ##### 9.1.2 Build Clinical Reference Sites ##### 9.1.3 Secure Distributor and Service Coverage ##### 9.1.4 Target Hospital Procurement Cycles #### 9.2 Export Entry Strategy ##### 9.2.1 Australia-New Zealand Platform Strategy ##### 9.2.2 APAC Clinical Reference Development ##### 9.2.3 Regional Distributor Enablement ##### 9.2.4 Cross-Border Service Infrastructure ### 10. Entry Mode Assessment #### 10.1 Direct Subsidiary Model #### 10.2 Authorized Distributor Model #### 10.3 Hybrid Sales and Service Model #### 10.4 Strategic Partnership Model ### 11. Capital and Timeline Estimation #### 11.1 Regulatory Setup Investment #### 11.2 Demo Equipment Investment #### 11.3 Service Network Investment #### 11.4 Commercial Scale-Up Timeline ### 12. Control vs Risk Trade-Off #### 12.1 Direct Channel Control #### 12.2 Distributor Execution Risk #### 12.3 Service Quality Risk #### 12.4 Regulatory Compliance Risk ### 13. Profitability Outlook #### 13.1 Equipment Gross Margin #### 13.2 Service Contract Margin #### 13.3 Software Recurring Revenue #### 13.4 Installed-Base Lifetime Value ### 14. Potential Partner List #### 14.1 Public Hospital Networks #### 14.2 Private Hospital Groups #### 14.3 Diagnostic Imaging Networks #### 14.4 Medical Equipment Distributors ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Complete Regulatory Registration ##### 15.2.2 Establish Clinical Reference Sites ##### 15.2.3 Expand National Service Coverage ##### 15.2.4 Scale Strategic Account Penetration ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage - Priority Metros and Regional Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 - Large Hospital and Imaging Network End Users ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Metro Distribution #### 3.2 Cohort 2 - Mid-Size Healthcare End Users ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and City Distribution #### 3.3 Cohort 3 - Specialist and Emerging Imaging End Users ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Regional Distribution #### 3.4 Cohort 4 - Institutional and Government End Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 Healthcare Expenditure Linkages ##### 4.1.2 Population Ageing and Disease Burden ##### 4.1.3 Hospital Capital Investment Cycles ##### 4.1.4 Import Dependency on Australia Medical Imaging Market #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Scanner Utilization and Procedure Volumes ##### 4.2.2 Equipment Replacement Cycles ##### 4.2.3 OEM Loyalty vs Price Sensitivity ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay for Premium Imaging ##### 4.3.2 Capital Cost Benchmarking ##### 4.3.3 Public vs Private Procurement Pricing ##### 4.3.4 Total Cost of Ownership Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Image Quality and Clinical Performance ##### 4.4.2 TGA Regulatory Compliance Awareness ##### 4.4.3 Domestic Support for Imported Systems ##### 4.4.4 After-Sales Service Expectations #### 4.5 Regional and Contextual Demand Factors ##### 4.5.1 Metropolitan Imaging Demand Hotspots ##### 4.5.2 Regional Access Requirements ##### 4.5.3 Clinical Peer Influence ##### 4.5.4 Digital Workflow Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Radiology Conferences and Clinical Events ##### 4.6.2 Digital Clinical Education ##### 4.6.3 Distributor Influence on Procurement ##### 4.6.4 OEM Reference Site Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Gaps Between Current Imaging Capacity and User Expectations #### 5.2 Latent Demand in Regional Markets #### 5.3 Willingness to Adopt AI and Portable Imaging #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us